SEATTLE, WA AND BOULDER, CO, USA I February 3, 2014 I Oncothyreon Inc. (ONTY) and Array BioPharma Inc. (ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
The trial (ClinicalTrials.gov Identifier NCT02025192) is a dose-escalation study in patients who have been previously treated with Herceptin® (trastuzumab) and Kadcyla® (ado-trastuzumab emtansine or TDM-1) for metastatic breast cancer. The primary objective is to determine the maximum-tolerated and/or recommended Phase 2 dose (MTD/RP2D) of ONT-380 in combination with the approved dose of either Xeloda or Herceptin or both. Secondary objectives include an evaluation of the safety and preliminary anti-tumor activity of the combinations. The study includes an expansion arm at the MTD/RP2D of ONT-380 in combination with both Xeloda and Herceptin, with the option to include expansion arms in combination with either agent alone. Patients with treated stable central nervous system (CNS) metastases are eligible for the dose escalation portions of the trial, while patients with CNS metastases which are either asymptomatic and untreated or progressive following local therapy may be included in the expansion cohorts. The trial is expected to enroll approximately 50 patients.
“The treatment or prevention of CNS metastases is perhaps the greatest unmet medical need for patients with HER2+ metastatic breast cancer,” said Diana Hausman, M.D., Chief Medical Officer of Oncothyreon. “ONT-380 has demonstrated preclinical activity in an animal model of brain metastases from HER2+ breast cancer. This trial is intended to identify clinically relevant combination therapy to advance the evaluation of the activity of ONT-380 in patients with CNS metastases.”
“We are encouraged by the rapid progress the Oncothyreon team has made since initiating our collaboration, now that important combination studies are enrolling,” said Michael Needle, M.D., Chief Medical Officer of Array. “We believe the unique pharmacologic properties of ONT-380, as the only oral, selective HER2 inhibitor, position it favorably as a potential new option for patients fighting breast cancer.”
About ONT-380
ONT-380 is an orally active, reversible and selective HER2 inhibitor. In multiple preclinical tumor models, ONT-380 was well tolerated and demonstrated significant dose-related tumor growth inhibition that was superior to Herceptin and Tykerb® (lapatinib). Additionally, in these models, ONT-380 demonstrated synergistic or additive tumor growth inhibition when dosed in combination with the standard-of-care therapeutics Herceptin or Taxotere® (docetaxel ). ONT-380 has also demonstrated superior activity, based on overall survival, compared to Tykerb® and to the investigational drug, neratinib, in an intracranial HER2+ breast cancer xenograft model.
A Phase 1 trial of ONT-380, with both dose-escalation and expansion components, has been completed in 50 patients, 43 of whom had HER2+ metastatic breast cancer. All HER2+ breast cancer patients had progressed on a Herceptin-containing regimen. In addition, over 80% had been treated with Tykerb, with many having progressed on therapy. In this study, ONT-380 demonstrated an acceptable safety profile; treatment-related adverse events were primarily Grade 1. Because ONT-380 is selective for HER2 and does not inhibit EGFR, there was a low incidence and severity of treatment-related diarrhea, rash and fatigue. Additionally, there were no treatment-related cardiac events or Grade 4 treatment-related adverse events reported. The maximum tolerated dose of ONT-380 established in this Phase 1 trial was 600 mg twice daily (BID). Twenty-two HER2+ breast cancer patients with measurable disease were treated with ONT-380 at doses greater than or equal to 600 mg BID. In this heavily pretreated patient population, there was a clinical benefit rate (partial response [n = 3] plus stable disease for at least 6 months [n = 3]) of 27%. Notably, two of the patients with partial responses during treatment with ONT-380 had confirmed progressions while on prior Tykerb – and Herceptin -containing regimens.
In addition to the Phase 1b trial of ONT-380 in combination with Xeloda and/or Herceptin described above, Oncothyreon expects to initiate a Phase 1b trial of ONT-380 in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. The Dana-Farber Cancer Institute, Boston, Massachusetts, is also currently conducting an investigator-sponsored trial of ONT-380 in combination with Herceptin in patients with brain metastases from HER2+ breast cancer.
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon’s goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin, within the next year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520), for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and MEK162 (Novartis). For more information on Array, please go to www.arraybiopharma.com
SOURCE: Array BioPharma
Post Views: 30
SEATTLE, WA AND BOULDER, CO, USA I February 3, 2014 I Oncothyreon Inc. (ONTY) and Array BioPharma Inc. (ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
The trial (ClinicalTrials.gov Identifier NCT02025192) is a dose-escalation study in patients who have been previously treated with Herceptin® (trastuzumab) and Kadcyla® (ado-trastuzumab emtansine or TDM-1) for metastatic breast cancer. The primary objective is to determine the maximum-tolerated and/or recommended Phase 2 dose (MTD/RP2D) of ONT-380 in combination with the approved dose of either Xeloda or Herceptin or both. Secondary objectives include an evaluation of the safety and preliminary anti-tumor activity of the combinations. The study includes an expansion arm at the MTD/RP2D of ONT-380 in combination with both Xeloda and Herceptin, with the option to include expansion arms in combination with either agent alone. Patients with treated stable central nervous system (CNS) metastases are eligible for the dose escalation portions of the trial, while patients with CNS metastases which are either asymptomatic and untreated or progressive following local therapy may be included in the expansion cohorts. The trial is expected to enroll approximately 50 patients.
“The treatment or prevention of CNS metastases is perhaps the greatest unmet medical need for patients with HER2+ metastatic breast cancer,” said Diana Hausman, M.D., Chief Medical Officer of Oncothyreon. “ONT-380 has demonstrated preclinical activity in an animal model of brain metastases from HER2+ breast cancer. This trial is intended to identify clinically relevant combination therapy to advance the evaluation of the activity of ONT-380 in patients with CNS metastases.”
“We are encouraged by the rapid progress the Oncothyreon team has made since initiating our collaboration, now that important combination studies are enrolling,” said Michael Needle, M.D., Chief Medical Officer of Array. “We believe the unique pharmacologic properties of ONT-380, as the only oral, selective HER2 inhibitor, position it favorably as a potential new option for patients fighting breast cancer.”
About ONT-380
ONT-380 is an orally active, reversible and selective HER2 inhibitor. In multiple preclinical tumor models, ONT-380 was well tolerated and demonstrated significant dose-related tumor growth inhibition that was superior to Herceptin and Tykerb® (lapatinib). Additionally, in these models, ONT-380 demonstrated synergistic or additive tumor growth inhibition when dosed in combination with the standard-of-care therapeutics Herceptin or Taxotere® (docetaxel ). ONT-380 has also demonstrated superior activity, based on overall survival, compared to Tykerb® and to the investigational drug, neratinib, in an intracranial HER2+ breast cancer xenograft model.
A Phase 1 trial of ONT-380, with both dose-escalation and expansion components, has been completed in 50 patients, 43 of whom had HER2+ metastatic breast cancer. All HER2+ breast cancer patients had progressed on a Herceptin-containing regimen. In addition, over 80% had been treated with Tykerb, with many having progressed on therapy. In this study, ONT-380 demonstrated an acceptable safety profile; treatment-related adverse events were primarily Grade 1. Because ONT-380 is selective for HER2 and does not inhibit EGFR, there was a low incidence and severity of treatment-related diarrhea, rash and fatigue. Additionally, there were no treatment-related cardiac events or Grade 4 treatment-related adverse events reported. The maximum tolerated dose of ONT-380 established in this Phase 1 trial was 600 mg twice daily (BID). Twenty-two HER2+ breast cancer patients with measurable disease were treated with ONT-380 at doses greater than or equal to 600 mg BID. In this heavily pretreated patient population, there was a clinical benefit rate (partial response [n = 3] plus stable disease for at least 6 months [n = 3]) of 27%. Notably, two of the patients with partial responses during treatment with ONT-380 had confirmed progressions while on prior Tykerb – and Herceptin -containing regimens.
In addition to the Phase 1b trial of ONT-380 in combination with Xeloda and/or Herceptin described above, Oncothyreon expects to initiate a Phase 1b trial of ONT-380 in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. The Dana-Farber Cancer Institute, Boston, Massachusetts, is also currently conducting an investigator-sponsored trial of ONT-380 in combination with Herceptin in patients with brain metastases from HER2+ breast cancer.
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon’s goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin, within the next year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520), for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and MEK162 (Novartis). For more information on Array, please go to www.arraybiopharma.com
SOURCE: Array BioPharma
Post Views: 30
